Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

M. Ridker, Paul; Z. Goldhaber, Samuel; Danielson, Ellie; Rosenberg, Yves; S. Eby, Charles; R. Deitcher, Steven; Cushman, Mary; Moll, Stephan; M. Kessler, Craig; Gregory Elliott, C.; Paulson, Rolf; Wong, Turnly; A. Bauer, Kenneth; A. Schwartz, Bruce; P. Miletich, Joseph; Bounameaux, Henri; J. Glynn, Robert

doi:10.1056/nejmoa035029

Public

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Published in New England Journal of Medicine • Apr 9, 2003

Authors:

Paul M. Ridker

Samuel Z. Goldhaber

Ellie Danielson

Abstract

BACKGROUND: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-ris...

Subject

Medicine

Warfarin

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!